Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Skip to main content

Contracts Grants Pricing Blog Glossary

Loading...

Kontrakk

The only workspace built for the work of government contracting.

Platform

Discovery feed
Pursuit board
Grants

Industries

Federal contractors
Defense primes
Nonprofit grants
Higher education

Resources

Help center
Developer docs

Company

About
Privacy
Terms of Service

© 2026 Kontrakk. All rights reserved.Government Contracts. Won with Confidence.

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Home
Grants
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

posted

synopsis

#PAR-25-069

Agency

National Institutes of Health

Code: HHS-NIH11

Description

No description available

Important Dates

Open Date

Nov 18, 2024

Close Date

Jan 7, 2027

CFDA Numbers

93.393

View on Grants.gov

More grants from National Institutes of Health

Investigator-Focused Award (Parent R35)
National Institutes of Health
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health
INCLUDE Project: Omics Phenotypes Related to Down Syndrome (X01 Clinical Trial Not Allowed)
National Institutes of Health
Clinical and Translational Science Award
National Institutes of Health
Limited Competition: Institutional Mentored Research Career Development Program for the Clinical and Translational Science Awards Program
National Institutes of Health